These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23274455)

  • 1. Ro 32-0432 attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.
    Singh TG; Rehni AK; Arora S
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):197-204. PubMed ID: 23274455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SU-6656, a selective Src kinase inhibitor, attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.
    Rehni AK; Singh TG; Arora S
    Nicotine Tob Res; 2012 Apr; 14(4):407-14. PubMed ID: 22102627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological modulation of farnesyltransferase subtype I attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice.
    Singh TG; Rehni AK; Arora SK
    Behav Pharmacol; 2013 Dec; 24(8):668-77. PubMed ID: 24196026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists.
    Biala G; Weglinska B
    Pharmacol Res; 2005 May; 51(5):483-8. PubMed ID: 15749464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal.
    Jackson A; Papke RL; Damaj MI
    Psychopharmacology (Berl); 2018 Jul; 235(7):1897-1905. PubMed ID: 29549391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of potential role of Rho GTPase in nicotine dependence-induced withdrawal syndrome in mice.
    Rather IIG; Behl T; Sehgal A; Singh S; Sharma N; Sharma A; Bhatia S; Al-Harrasi A; Khan N; Khan H; Bungau S
    Environ Sci Pollut Res Int; 2022 Mar; 29(12):17417-17424. PubMed ID: 34665416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral characterization of early nicotine withdrawal in the mouse: a potential model of acute dependence.
    Kim B; Im HI
    Behav Brain Funct; 2024 Jan; 20(1):1. PubMed ID: 38218838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats.
    Paterson NE; Markou A
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):64-72. PubMed ID: 14712336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcysteine decreased nicotine reward-like properties and withdrawal in mice.
    Bowers MS; Jackson A; Maldoon PP; Damaj MI
    Psychopharmacology (Berl); 2016 Mar; 233(6):995-1003. PubMed ID: 26676982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of continuous nicotine infusion produces somatic but not behavioral signs of withdrawal in mice.
    Kwilasz AJ; Harris LS; Vann RE
    Pharmacol Biochem Behav; 2009 Nov; 94(1):114-8. PubMed ID: 19660491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences in the reward deficit and somatic signs associated with precipitated nicotine withdrawal in rats.
    Tan S; Xue S; Behnood-Rod A; Chellian R; Wilson R; Knight P; Panunzio S; Lyons H; Febo M; Bruijnzeel AW
    Neuropharmacology; 2019 Dec; 160():107756. PubMed ID: 31487496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnitude of open-field thigmotaxis during mecamylamine-precipitated nicotine withdrawal in rats is influenced by mecamylamine dose, duration of nicotine infusion, number of withdrawal episodes, and age.
    Harris AC
    Pharmacol Biochem Behav; 2021 Jun; 205():173185. PubMed ID: 33831460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice.
    Biała G; Budzyńska B; Kruk M
    Pharmacol Rep; 2005; 57(6):755-60. PubMed ID: 16382193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats.
    Shram MJ; Siu EC; Li Z; Tyndale RF; Lê AD
    Psychopharmacology (Berl); 2008 Jun; 198(2):181-90. PubMed ID: 18385986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bupropion attenuates nicotine abstinence syndrome in the rat.
    Malin DH; Lake JR; Smith TD; Khambati HN; Meyers-Paal RL; Montellano AL; Jennings RE; Erwin DS; Presley SE; Perales BA
    Psychopharmacology (Berl); 2006 Mar; 184(3-4):494-503. PubMed ID: 16163521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse.
    Damaj MI; Kao W; Martin BR
    J Pharmacol Exp Ther; 2003 Nov; 307(2):526-34. PubMed ID: 12970387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat.
    Malin DH; Lake JR; Carter VA; Cunningham JS; Hebert KM; Conrad DL; Wilson OB
    Psychopharmacology (Berl); 1994 Jun; 115(1-2):180-4. PubMed ID: 7862893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome.
    Hildebrand BE; Nomikos GG; Hertel P; Schilström B; Svensson TH
    Brain Res; 1998 Jan; 779(1-2):214-25. PubMed ID: 9473676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine abstinence in the mouse.
    Isola R; Vogelsberg V; Wemlinger TA; Neff NH; Hadjiconstantinou M
    Brain Res; 1999 Dec; 850(1-2):189-96. PubMed ID: 10629764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mecamylamine elicits withdrawal-like signs in rats following a single dose of nicotine.
    Harris AC; Manbeck KE; Schmidt CE; Shelley D
    Psychopharmacology (Berl); 2013 Jan; 225(2):291-302. PubMed ID: 22868410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.